|
Please join an important webinar NEXT TUESDAY focusing on how monoclonal antibodies and other therapeutics can help prevent serious illness from COVID-19. This webinar will feature Michael R. Anderson, MD, a Senior Advisor to HHS’ Assistant Secretary for Preparedness and Response (ASPR). Read more about the webinar and Dr. Anderson below.
The Critical Role of Monoclonal Antibodies as the COVID-19 Pandemic Continues
Tuesday, August 10
4:00-5:00 p.m. ET
Join the day of the session
If you prefer to join by phone: 833-568-8864
When prompted, enter meeting/webinar ID: 160 055 0780 and passcode: 828587
We know that this webinar conflicts with our 2020 Uniform Data System data trends webinar. Please know that we will record this webinar and share the recording. However, we strongly encourage providers who have questions about COVID-19 treatments to attend this webinar so they can participate in the Q&A portion.
About the Webinar
In the continued fight against COVID-19, we have seen how important monoclonal antibodies and other therapeutics are in helping prevent serious illness. As viral variants arise and spread, it is increasingly critical that health care providers have the latest treatment information at their fingertips. Dr. Anderson will share updates on available COVID-19 therapeutics including medication efficacy, new administration routes and novel treatments in the pipeline, fee reimbursement resources, and provider and patient tools and fact sheets. Dr. Anderson and HRSA representatives will also be available for a Q&A to answer providers’ questions about these important COVID-19 therapies.
About the Presenter
Michael R. Anderson, MD, MBA, FAAP, FCCM, FAARC, is a pediatric critical care physician, health care executive, child advocate, and a nationally renowned expert in disaster response and health policy. During the COVID-19 pandemic, he was asked to join HHS full time and is currently a Senior Advisor to HHS’ ASPR in Washington, D.C. He is a key leader on the COVID-19 monoclonal antibody therapeutics team and has deployed with federal COVID-19 monoclonal antibody administration teams and focused on stakeholder engagement, product distribution, and the creation of innovative infusion centers aimed at saving lives and preserving hospital capacity.
|
Sign up for eNews
Connect with HRSA
